Crossfire Oncology (BAL0891) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 2

Crossfire Oncology (BAL0891) General Information

Description

Developer of a mitotic checkpoint inhibitor designed to interrupt abnormal cell division in tumor cells. The company offers a compound that affects mitotic regulation, enabling individuals with advanced solid tumors to undergo treatment that impacts tumor growth.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • Oss
  • Netherlands
Primary Industry
Drug Discovery
Acquirer
SillaJen
Vertical(s)
Oncology
Corporate Office
  • Oss
  • Netherlands

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Crossfire Oncology (BAL0891) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Crossfire Oncology (BAL0891)‘s full profile, request access.

Request a free trial

Crossfire Oncology (BAL0891) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Crossfire Oncology (BAL0891)‘s full profile, request access.

Request a free trial

Crossfire Oncology (BAL0891) FAQs

  • Where is Crossfire Oncology (BAL0891) headquartered?

    Crossfire Oncology (BAL0891) is headquartered in Oss, Netherlands.

  • What industry is Crossfire Oncology (BAL0891) in?

    Crossfire Oncology (BAL0891)’s primary industry is Drug Discovery.

  • Is Crossfire Oncology (BAL0891) a private or public company?

    Crossfire Oncology (BAL0891) is a Private company.

  • What is the current valuation of Crossfire Oncology (BAL0891)?

    The current valuation of Crossfire Oncology (BAL0891) is .

  • What is Crossfire Oncology (BAL0891)’s current revenue?

    The current revenue for Crossfire Oncology (BAL0891) is .

  • Who are Crossfire Oncology (BAL0891)’s investors?

    Basilea Pharmaceutica and Crossfire Oncology have invested in Crossfire Oncology (BAL0891).

  • When was Crossfire Oncology (BAL0891) acquired?

    Crossfire Oncology (BAL0891) was acquired on 20-Sep-2022.

  • Who acquired Crossfire Oncology (BAL0891)?

    Crossfire Oncology (BAL0891) was acquired by SillaJen.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process